Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 5, 2014, Pages 551-555

  Dyson, Jessica Katharine ^a   Hudson, Mark ^a   McPherson, Stuart ^b  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antiviral therapy; Chemotherapy; Hepatitis B; Immunosuppression; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; RITUXIMAB; TENOFOVIR; VINCRISTINE; VIRUS DNA; IMMUNOSUPPRESSIVE AGENT;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHOLESTATIC HEPATITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENERAL CONDITION DETERIORATION; HEPATITIS B; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LARGE CELL LYMPHOMA; LIVER BIOPSY; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER FUNCTION TEST; LYMPHADENOPATHY; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; NUTRITIONAL DISORDER; PATIENT MONITORING; PRURITUS; RECURRENT VIRUS INFECTION; SEROLOGY; SUBMANDIBULAR GLAND; SWELLING; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION; BLOOD; CHEMICALLY INDUCED; HEPATITIS B VIRUS; LIVER; PATHOLOGY; VIROLOGY;

AGED; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE;

EID: 84907984807     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-5-551     Document Type: Article

References (26)

1. Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR CDC 2008;57(RR-8):1-20.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
3. Hwang JP, Fisch MJ, Lok AS et al. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534.
4. Day FL, Link E, Thursky K et al. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011;7:141-7.
5. Tran TT, Rakoski MO, Martin P et al. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Therapeut 2010;31:240-6.
6. Zurawska U, Hicks LK, Woo G et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012;30:3167-73.
7. Cooke GS, Main J, Thursz MR. Treatment for hepatitis B. BMJ 2010;340:b5429.
8. McPherson S, Valappil M, Moses SE et al. Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. J Viral Hepatitis 2013;20:638-44.
9. Hwang JP, Vierling JM, Zelenetz AD et al. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer 2012;20:2999-3008.
10. Rehermann B, Ferrari C, Pasquinelli C et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med 1996;2:1104-8.
11. Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut 2010;59:1430-45.
12. Lok AS, Liang RH, Chiu EK et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
13. Markovic S, Drozina G, Vovk M et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepato-gastroenterology 1999;46:2925-30.
14. Nakamura Y, Motokura T, Fujita A et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996;78:2210-15.
15. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107-9.
16. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
17. Uhm JE, Kim K, Lim TK et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:463-8.
18. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68.
19. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11.
20. Huang YH, Hsiao LT, Hong YC et al. Randomised controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013;31:2765-72.
21. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:3147-53.
22. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-9.
23. Hsu C, Hsiung CA, Su IJ et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomised trial. Hepatology 2008;47:844-53.
24. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-28.
25. Sarri G, Westby M, Bermingham S et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ 2013;346:f3893.
26. National Institute for Health and Care Excellence. Hepatitis B (chronic): Diagnosis and management of chronic hepatitis B in children, young people and adults. CG165. London: NICE, 2013. www.nice.org.uk/guidance/cg165 [Accessed 4 August 2014]